Evidence map›Paper›PMID 39787198›Full record

ArticlePloS one2025

Clinical, histopathological and parasitological follow-up of dogs naturally infected by Leishmania infantum before and after miltefosine treatment and associated therapies.

Amábilli de Souza Rosar, Carolina Leite Martins, Álvaro Menin, Carolina Reck, Edmundo Carlos Grisard, Glauber Wagner, Mário Steindel, Patricia Hermes Stoco, Patricia Flavia Quaresma

Abstract read
In one paragraph

Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Isolation ofOne health (Amsterdam, Netherlands) · 2026
    Article
  3. Article
  4. Osh2 mediatesAntimicrobial agents and chemotherapy · 2025
    Article
  5. Treatment ofMicroorganisms · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Amábilli de Souza RosarDepartment of Microbiology, Immunology and Parasitology, Laboratory of Protozoology, Federal University of Santa Catarina, Florianópolis, SC, Brazil.
Carolina Leite MartinsDepartment of Microbiology, Immunology and Parasitology, Laboratory of Protozoology, Federal University of Santa Catarina, Florianópolis, SC, Brazil.
Álvaro MeninDepartment of Biosciences and One Health, Federal University of Santa Catarina, Curitibanos, SC, Brazil.
Carolina ReckVERTÁ, Laboratory of Veterinary Diagnostic, Institute of Veterinary Research and Diagnostic, Curitibanos, SC, Brazil.
Edmundo Carlos GrisardDepartment of Microbiology, Immunology and Parasitology, Laboratory of Protozoology, Federal University of Santa Catarina, Florianópolis, SC, Brazil.
Glauber WagnerDepartment of Microbiology, Immunology and Parasitology, Laboratory of Protozoology, Federal University of Santa Catarina, Florianópolis, SC, Brazil.
Mário SteindelDepartment of Microbiology, Immunology and Parasitology, Laboratory of Protozoology, Federal University of Santa Catarina, Florianópolis, SC, Brazil.
Patricia Hermes StocoDepartment of Microbiology, Immunology and Parasitology, Laboratory of Protozoology, Federal University of Santa Catarina, Florianópolis, SC, Brazil.
Patricia Flavia QuaresmaDepartment of Microbiology, Immunology and Parasitology, Laboratory of Protozoology, Federal University of Santa Catarina, Florianópolis, SC, Brazil.ORCID 0000-0001-8274-4166

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In Brazil, Visceral Leishmaniases is caused by Leishmania infantum, and domestic dogs are the main reservoirs in its urban transmission cycle. As an alternative to euthanizing dogs, miltefosine has been used to treat canine visceral leishmaniasis since 2016. In this study, we have assessed the efficacy of miltefosine for treating canine visceral leishmaniasis in a new endemic area through follow-up of naturally infected dogs was evaluated. The clinical, parasitological, and histopathological characteristics of 21 dogs naturally infected with L. infantum were assessed at three time points: on the day before initiating miltefosine treatment (T0), immediately after treatment completion (T1), and 6 months after treatment completion (T2). Three dogs were treated exclusively with miltefosine, while eighteen received combination therapy with miltefosine with other treatments such as allopurinol, domperidone and immunotherapy. Skin biopsies were obtained from the abdomen to assess inflammatory responses and to quantify parasite loads using qPCR. The parasites were isolated using aspirates acquired from popliteal lymph nodes. Molecular and parasitological analyses confirmed the presence of L. infantum in all dogs, validating the effectiveness of skin and lymph node samples for diagnosis. The clinical conditions of the infected animals were improved and the skin parasite load decreased after treatment, even when distinct combination therapies were performed. The histopathological assessment revealed a miltefosine-induced reduction in the inflammatory response and a decrease in amastigotes number. Furthermore, a positive correlation was established between the reduction in parasite load and the enhancement of clinical scoring, as well as a reduction in the skin inflammatory response. Our findings suggest that miltefosine-based combination therapies reduce skin parasite load and improve clinical outcomes, while the dogs treated with miltefosine alone showed increased parasitic load and worsened clinical staging at T2. Considering this data belonging to a recent transmission area, treatment strategy suggests effective in controlling canine visceral leishmaniasis.

Indexed as

Antiprotozoal AgentsDog DiseasesLeishmania infantumLeishmaniasis, VisceralPhosphorylcholineAllopurinolAnimalsBrazilDogsFemaleFollow-Up StudiesMaleParasite LoadAllopurinolAntiprotozoal AgentsmiltefosinePhosphorylcholine

Identifiers

PMID39787198
PMCPMC11717219

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.